Cue Biopharma Q3 EPS $(0.24) Beats $(0.34) Estimate, Sales $2.10M Beat $1.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cue Biopharma reported Q3 losses of $(0.24) per share, beating the analyst consensus estimate of $(0.34) by 29.41%. This is a 22.58% increase over losses from the same period last year. The company also reported quarterly sales of $2.10 million, beating the analyst consensus estimate of $1.13 million by 85.84%. This is a 2.99K% increase over sales from the same period last year.
November 09, 2023 | 10:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cue Biopharma reported better than expected Q3 earnings and sales, which could positively impact the stock price.
Cue Biopharma reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100